home / stock / arch:cc / arch:cc quote
Last: | $3.95 |
---|---|
Change Percent: | 1.28% |
Open: | $3.98 |
Close: | $3.95 |
High: | $3.98 |
Low: | $3.86 |
Volume: | 23,777 |
Last Trade Date Time: | 05/06/2022 04:55:13 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.95 | $3.98 | $3.95 | $3.98 | $3.86 | 23,777 | 05-06-2022 |
$3.9 | $3.9 | $3.9 | $3.9 | $3.9 | 2,304 | 05-05-2022 |
$3.94 | $3.87 | $3.94 | $4 | $3.86 | 26,576 | 05-04-2022 |
$3.87 | $3.94 | $3.87 | $3.94 | $3.85 | 16,732 | 05-03-2022 |
$3.95 | $3.99 | $3.95 | $3.99 | $3.93 | 2,036 | 05-02-2022 |
$3.94 | $3.9 | $3.94 | $3.98 | $3.9 | 8,676 | 04-29-2022 |
$3.94 | $4.09 | $3.94 | $4.09 | $3.9 | 10,226 | 04-28-2022 |
$4 | $4.01 | $4 | $4.04 | $3.97 | 9,564 | 04-27-2022 |
$3.92 | $4 | $3.92 | $4 | $3.92 | 3,601 | 04-26-2022 |
$4 | $4 | $4 | $4.06 | $3.96 | 37,800 | 04-25-2022 |
$4.04 | $4.05 | $4.04 | $4.05 | $3.96 | 11,556 | 04-22-2022 |
$4.06 | $4.23 | $4.06 | $4.23 | $4.06 | 34,096 | 04-21-2022 |
$4.2 | $4.2 | $4.2 | $4.2 | $4.15 | 17,683 | 04-20-2022 |
$4.18 | $4.09 | $4.18 | $4.2 | $4.09 | 36,675 | 04-19-2022 |
$4.15 | $4.07 | $4.15 | $4.15 | $4.02 | 22,803 | 04-18-2022 |
$4.07 | $4.04 | $4.07 | $4.13 | $4.04 | 26,004 | 04-15-2022 |
$4.07 | $4.04 | $4.07 | $4.13 | $4.04 | 25,704 | 04-14-2022 |
$4.05 | $4.12 | $4.05 | $4.13 | $4 | 49,905 | 04-13-2022 |
$4 | $4.08 | $4 | $4.08 | $3.99 | 38,186 | 04-12-2022 |
$4.07 | $4.09 | $4.07 | $4.09 | $4.03 | 7,924 | 04-11-2022 |
News, Short Squeeze, Breakout and More Instantly...
Arch Biopartners Inc. Company Name:
ARCH:CC Stock Symbol:
TSXVC Market:
TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from St. Michael’s Hospital, a site of Unity Health Toronto, has joined the Phase II tria...
TORONTO, April 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Anesthesia Clinical Trials Unit (ACTU), an academic research organization in the Department of Anesthesia and Pa...
TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevent...